Cimzia® (certolizumab pegol)
demonstrates durable
efficacy
Through pooled data from the Cimzia arms of the
CIMPASI 1 and CIMPASI 2 trials.2
Cimzia is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.1
Due to the emerging biosimilar market, trusts are being encouraged to use the best value biologic as the first line option.13 In addition to financial costs, it is important to consider the wider impact on the patient, their family and the NHS when a patient is on a treatment journey e.g. switching treatments, repeated hospital visits, loss of work days.14
Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk and hpra.ie/homepage/about-us/report-an-issue.
Adverse events should also be reported to UCB Pharma Ltd Email: UCBCares.UK@ucb.com and UCBCares.IE@ucb.com.
Help us to grow our resource the way you want it to grow.